BioSpace News Archive

A strong recurring message of individualizing patient care is echoed throughout the American Diabetes Association’s Standards of Medical Care in Diabetes—2020 (Standards of Care) published today.

Fertilizer Canada, in partnership with the Paramedic Association of Canada, Canadian Association of Fire Chiefs and the Canadian Association of Chiefs of Police, launched an update of the Anhydrous Ammonia Awareness for First Responders awareness program, which gives the first responder community educational resources they need to understand the use and handling of agricultural anhydrous ammonia.

e5 Pharma, LLC., today announced the U.S. launch of Diazoxide, USP Oral Suspension, the first generic version of the reference listed drug, Proglycem®. e5 Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) using the Competitive Generic Therapy (CGT) Pathway.

The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has opened a new fund to provide copayment and premium assistance to Medicare patients living with chronic heart failure.

XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced rights offering (the “Rights Offering”). At the closing, XOMA sold and issued an aggregate of 626,805 shares of its common stock (the “Common Stock”) pursuant to the exercise of subscriptions in the Rights Offering from its existing stockholders.

Health Canada is advising consumers that it has seized three unauthorized eye drop products from two Floy Beauty stores in Toronto, Ontario, because they may pose serious health risks.

The Jackson Laboratory (JAX) has received $2.5 million from The Mark Foundation for Cancer Research to study in mice the influence of host genetics on response to immunotherapy.

Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare investors Canaan and Australia’s Medical Research Commercialisation Fund managed by Brandon Capital (“MRCF”).

Demonstrates Evoke® ECAP-Controlled Closed-Loop SCS Provides Statistically Superior Pain Relief Compared to Open-Loop SCS

Hutchison China MediTech Limited announces that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Priority Review status to the New Drug Application for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine tumors.